Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.56% | -5.94% | -9.78% | -4.65% | 18.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.56% | -5.94% | -9.78% | -4.65% | 18.96% |
| Cost of Revenue | -28.33% | -19.32% | -23.54% | -11.58% | 17.73% |
| Gross Profit | -5.66% | 3.18% | -0.35% | 0.66% | 19.94% |
| SG&A Expenses | 2.23% | 23.00% | 17.56% | 17.43% | 2.61% |
| Depreciation & Amortization | 38.04% | 54.06% | 72.06% | 68.12% | 21.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.77% | 3.99% | 3.54% | 8.24% | 10.86% |
| Operating Income | -55.70% | -59.68% | -80.37% | -110.27% | 141.14% |
| Income Before Tax | -49.32% | 43.72% | -67.63% | -176.67% | 210.69% |
| Income Tax Expenses | 148.98% | 98.26% | 273.68% | -190.35% | 156.32% |
| Earnings from Continuing Operations | -89.09% | -386.36% | -73.63% | -172.57% | 237.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.09% | -386.36% | -73.63% | -172.57% | 237.27% |
| EBIT | -55.70% | -59.68% | -80.37% | -110.27% | 141.14% |
| EBITDA | -25.97% | -28.10% | -42.93% | -49.01% | 83.59% |
| EPS Basic | -91.58% | -317.78% | -80.00% | -159.94% | 234.39% |
| Normalized Basic EPS | -61.43% | -102.09% | -99.13% | -96.72% | 208.78% |
| EPS Diluted | -91.58% | -332.56% | -80.00% | -159.94% | 234.39% |
| Normalized Diluted EPS | -61.43% | -102.16% | -99.13% | -96.72% | 208.78% |
| Average Basic Shares Outstanding | 31.42% | 31.53% | 31.89% | 21.08% | 2.04% |
| Average Diluted Shares Outstanding | 31.42% | 27.12% | 31.89% | 21.08% | 2.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |